Effects of the 5′-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2

Thomas D. Gillis; Stephen L. Bearne

doi:10.1002/cmdc.202200399

Effects of the 5′-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2

Decision Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	e202200399
Journal	ChemMedChem
Volume	17
Issue number	23
DOIs	https://doi.org/10.1002/cmdc.202200399
Publication status	Published - Dec 5 2022

ASJC Scopus Subject Areas

Drug Discovery
Molecular Medicine
Biochemistry
Pharmacology, Toxicology and Pharmaceutics(all)
Pharmacology
Organic Chemistry

Keywords

CTP synthase
activation
antiviral
filaments
inhibition kinetics

Access to Document

10.1002/cmdc.202200399

Fingerprint

Dive into the research topics of 'Effects of the 5′-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2'. Together they form a unique fingerprint.

Reports Outline COVID-19 Study Findings from Dalhousie University (Effects of the 5 '-triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir On Ctp Synthase Catalysis and Filament Formation: Implications for Repurposing ...)
Stephen L., B.
11/21/22
1 item of Media coverage
Press/Media: Research

Cite this

Effects of the 5′-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2. / Gillis, Thomas D.; Bearne, Stephen L.
In: ChemMedChem, Vol. 17, No. 23, e202200399, 05.12.2022.

Research output: Contribution to journal › Article › peer-review

@article{2a39567dcf204855a7c47cf9247f769b,

title = "Effects of the 5′-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2",

keywords = "CTP synthase, activation, antiviral, filaments, inhibition kinetics",

author = "Gillis, {Thomas D.} and Bearne, {Stephen L.}",

note = "Publisher Copyright: {\textcopyright} 2022 Wiley-VCH GmbH.",

year = "2022",

month = dec,

day = "5",

doi = "10.1002/cmdc.202200399",

language = "English",

volume = "17",

journal = "ChemMedChem",

issn = "1860-7179",

publisher = "John Wiley and Sons Ltd",

number = "23",

}

TY - JOUR

T1 - Effects of the 5′-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation

T2 - Implications for Repurposing Antiviral Agents against SARS-CoV-2

AU - Gillis, Thomas D.

AU - Bearne, Stephen L.

PY - 2022/12/5

Y1 - 2022/12/5

KW - CTP synthase

KW - activation

KW - antiviral

KW - filaments

KW - inhibition kinetics

UR - http://www.scopus.com/inward/record.url?scp=85141188655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141188655&partnerID=8YFLogxK

U2 - 10.1002/cmdc.202200399

DO - 10.1002/cmdc.202200399

M3 - Article

C2 - 36184568

AN - SCOPUS:85141188655

SN - 1860-7179

VL - 17

JO - ChemMedChem

JF - ChemMedChem

IS - 23

M1 - e202200399

ER -

Effects of the 5′-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2

ASJC Scopus Subject Areas

Keywords

Access to Document

Other files and links

Fingerprint

Press/Media

Reports Outline COVID-19 Study Findings from Dalhousie University (Effects of the 5 '-triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir On Ctp Synthase Catalysis and Filament Formation: Implications for Repurposing ...)

Cite this